Companion Diagnostic Cancer Biomarkers Market by Product Type (Protein Biomarkers ,Genetic Biomarkers, Other Cancer Biomarkers); by Applications (Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Gastric, Others); by Regional Outlook (U.S., Rest of North America, France, UK, Germany, Spain, Italy, Rest of Europe, China, Japan, India, Southeast Asia, Rest of Asia Pacific, GCC Countries, Southern Africa, Rest of MEA, Brazil, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2018 - 2026

Report ID :AMI-87 | Category : Biotechnology | Published Date :July, 2017 | Pages : 300 | Format :PDF
Buy Now!

Industry trends

Companion diagnostics (CDx) are in vitro devices, assays or imaging tools which are used in combination with cancer biomarkers that provide critical information regarding patients’ condition and efficiency of the treatment. This enables healthcare professionals to determine if the benefits of the treatments outweigh the associated risks and subsequently prescribe the most appropriate treatment.

The companion diagnostic cancer biomarkers market for companion diagnostics cancer biomarkers is fueled by the growing incidents of cancer and the need for better treatment solutions. In the present scenario where the prescription of most cancer treatments is predominantly based on trial and error, companion diagnostics (CDx) give a certain assurance of more efficient and safer pharmacotherapy. Numerous FDA approved companion diagnostics are being developed for breast cancer, colorectal cancer, lung cancer, gastric cancer and melanoma. Companion diagnostics standards are equivalent to the requirements and regulations to that of the related drugs.

The aligning of revenue among the stakeholders remains a major challenge. The companies that are developing companion diagnostics are caught between the conflicting demands of two major stakeholders i.e., the companies that are directly involved in the development of the drugs or companion biomarkers and the providers/payers. The regulation criteria are becoming more demanding in terms of development period between drug and companion diagnostics.

Research and development of predictive biomarkers in oncology plays a significant role in profitable commercialization of companion diagnostics. The Gleevec (Imatinib) and Herceptin(trastuzumab) are two of the most commercially successful drugs that are attributed to the acceptance and popularity of companion diagnostics. Before prescription, both of these drugs need companion diagnostics for testing. From the initial beginning of a few oncology biomarkers with companion diagnostics, the companion diagnostic cancer biomarkers market has expanded to several therapeutic areas and the number of combinations has grown manifolds.

Global Companion Diagnostics Cancer Biomarkers Market, By Application, 2016 & 2021 (USD Million)

Companion Diagnostic Cancer Biomarkers Market

Companion Diagnostic Cancer Biomarkers Market, by Application

The application of companion diagnostics with cancer biomarkers in the treatment of breast cancer is accounted for US$ 960 Mn in 2016 and expected to show sustainable growth during the forecast period. The growth is attributed to the rise of breast cancer awareness programs and as the demand and development of CDx for detection of biomarkers for breast cancer.

Companion Diagnostic Cancer Biomarker Market, by Region

North America dominated the companion diagnostic cancer biomarkers market in terms of revenue accounting for approximately US$ 980 Mn in 2016 accounting for 42.6% of the global market, followed by Europe. The major share is attributed to the high investments in research and development in the region, high demand for companion diagnostics cancer biomarkers from the medical industry and demonstrated support from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). Another important reason for the growth in North America is a relatively better insurance infrastructure assuring predictable reimbursement. 

Competitive Market Share

The companion diagnostic cancer biomarkers market report provides both, qualitative and quantitative research of the market, as well as it helps to gain important insights of current and future market and trending technologies adopted by the key players. The report also offers extensive research on the key players in this market and detailed insights on the competitiveness of these players. The key business strategies such as mergers and acquisitions(M&A), affiliations, collaborations, and contracts adopted by the major players are also recognized and analyzed in the report. For each company, the report recognizes their manufacturing base, competitors, product type, application and specification, pricing, and gross margin.

Some of the key participants of global companion diagnostic cancer biomarkers market are Hoffmann-La Roche AG, Agilent Technologies, Inc., Qiagen N.V., Thermo Fisher Scientific Inc., Abbott Laboratories, Inc., Biomérieux SA, Danaher Corporation, Illumina, Inc., Myriad Genetics, Inc., Arup Laboratories Inc., Sysmex Corporation, Hologic Inc., Novartis AG, Almac Group and Abnova Corporation amongst others.

Companion Diagnostic Cancer Biomarkers MarketCompanion Diagnostic Cancer Biomarkers Market

1.    Introduction

1.1.   Market Scope

1.2.   Market Segmentation

1.3.   Methodology

1.4.   Assumptions

2.    Companion Diagnostic Cancer Biomarkers Market Snapshot

3.    Executive Summary: Companion Diagnostic Cancer Biomarkers Market

4.    Qualitative Analysis: Companion Diagnostic Cancer Biomarkers Market

4.1.   Introduction

4.1.1.   Product Definition

4.1.2.   Industry Development

4.2.   Market Dynamics

4.2.1.   Drivers

4.2.2.   Restraints

4.2.3.   Opportunities

4.3.   Trends in Market

5.    Global Companion Diagnostic Cancer Biomarkers Market Analysis and Forecasts, 2018 – 2026

5.1.   Overview

5.1.1.   Global Market Revenue (US$ Mn) and Forecasts

5.2.   Global Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Product Type

5.2.1.   Protein Biomarkers

5.2.1.1.    Definition

5.2.1.2.    Market Penetration

5.2.1.3.    Market Revenue Expected to Increase by 2026

5.2.1.4.    Compound Annual Growth Rate (CAGR)

5.2.2.   Genetic Biomarkers

5.2.2.1.    Definition

5.2.2.2.    Market Penetration

5.2.2.3.    Market Revenue Expected to Increase by 2026

5.2.2.4.    Compound Annual Growth Rate (CAGR)

5.2.3.   Other Cancer Biomarkers

5.2.3.1.    Definition

5.2.3.2.    Market Penetration

5.2.3.3.    Market Revenue Expected to Increase by 2026

5.2.3.4.    Compound Annual Growth Rate (CAGR)

5.3.   Key Segment for Channeling Investments

5.3.1.   By Product Type

6.    Global Companion Diagnostic Cancer Biomarkers Market Analysis and Forecasts, 2018 – 2026

6.1.   Overview

6.2.   Global Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Applications

6.2.1.   Breast Cancer

6.2.1.1.    Definition

6.2.1.2.    Market Penetration

6.2.1.3.    Market Revenue Expected to Increase by 2026

6.2.1.4.    Compound Annual Growth Rate (CAGR)

6.2.2.   Lung Cancer

6.2.2.1.    Definition

6.2.2.2.    Market Penetration

6.2.2.3.    Market Revenue Expected to Increase by 2026

6.2.2.4.    Compound Annual Growth Rate (CAGR)

6.2.3.   Melanoma

6.2.3.1.    Definition

6.2.3.2.    Market Penetration

6.2.3.3.    Market Revenue Expected to Increase by 2026

6.2.3.4.    Compound Annual Growth Rate (CAGR)

6.2.4.   Colorectal Cancer

6.2.4.1.    Definition

6.2.4.2.    Market Penetration

6.2.4.3.    Market Revenue Expected to Increase by 2026

6.2.4.4.    Compound Annual Growth Rate (CAGR)

6.2.5.   Gastric

6.2.5.1.    Definition

6.2.5.2.    Market Penetration

6.2.5.3.    Market Revenue Expected to Increase by 2026

6.2.5.4.    Compound Annual Growth Rate (CAGR)

6.2.6.   Others (Cervical, Kidney, Leukemia, etc.)

6.2.6.1.    Definition

6.2.6.2.    Market Penetration

6.2.6.3.    Market Revenue Expected to Increase by 2026

6.2.6.4.    Compound Annual Growth Rate (CAGR)

6.3.   Key Segment for Channeling Investments

6.3.1.   By Applications

7.    North America Companion Diagnostic Cancer Biomarkers Market Analysis and Forecasts, 2018 – 2026

7.1.   Overview

7.1.1.   North America Market Revenue (US$ Mn)

7.2.   North America Market Revenue (US$ Mn) and Forecasts, By Product Type

7.2.1.   Protein Biomarkers

7.2.2.   Genetic Biomarkers

7.2.3.   Other Cancer Biomarkers

7.3.   North America Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Applications

7.3.1.   Breast Cancer

7.3.2.   Lung Cancer

7.3.3.   Melanoma

7.3.4.   Colorectal Cancer

7.3.5.   Gastric

7.3.6.   Others (Cervical, Kidney, Leukemia, etc.)

7.4.   North America Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Country

7.4.1.   U.S.

7.4.1.1.    U.S. Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Product Type

7.4.1.1.1.    Protein Biomarkers

7.4.1.1.2.    Genetic Biomarkers

7.4.1.1.3.    Other Cancer Biomarkers

7.4.1.2.    U.S. Market Revenue (US$ Mn) and Forecasts, By Applications

7.4.1.2.1.    Breast Cancer

7.4.1.2.2.    Lung Cancer

7.4.1.2.3.    Melanoma

7.4.1.2.4.    Colorectal Cancer

7.4.1.2.5.    Gastric

7.4.1.2.6.    Others (Cervical, Kidney, Leukemia, etc.)

7.4.2.   Rest of North America

7.4.2.1.    Rest of North America Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Product Type

7.4.2.1.1.    Protein Biomarkers

7.4.2.1.2.    Genetic Biomarkers

7.4.2.1.3.    Other Cancer Biomarkers

7.4.2.2.    Rest of North America Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Applications

7.4.2.2.1.    Breast Cancer

7.4.2.2.2.    Lung Cancer

7.4.2.2.3.    Melanoma

7.4.2.2.4.    Colorectal Cancer

7.4.2.2.5.    Gastric

7.4.2.2.6.    Others (Cervical, Kidney, Leukemia, etc.)

7.5.   Key Segment for Channeling Investments

7.5.1.   By Country

7.5.2.   By Product Type

7.5.3.   By Applications

8.    Europe Companion Diagnostic Cancer Biomarkers Market Analysis and Forecasts, 2018 – 2026

8.1.   Overview

8.1.1.   Europe Market Revenue (US$ Mn)

8.2.   Europe Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Product Type

8.2.1.   Protein Biomarkers

8.2.2.   Genetic Biomarkers

8.2.3.   Other Cancer Biomarkers

8.3.   Europe Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Applications

8.3.1.   Breast Cancer

8.3.2.   Lung Cancer

8.3.3.   Melanoma

8.3.4.   Colorectal Cancer

8.3.5.   Gastric

8.3.6.   Others (Cervical, Kidney, Leukemia, etc.)

8.4.   Europe Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Country

8.4.1.   France

8.4.1.1.    France Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Product Type

8.4.1.1.1.    Protein Biomarkers

8.4.1.1.2.    Genetic Biomarkers

8.4.1.1.3.    Other Cancer Biomarkers

8.4.1.2.    France Market Revenue (US$ Mn) and Forecasts, By Applications

8.4.1.2.1.    Breast Cancer

8.4.1.2.2.    Lung Cancer

8.4.1.2.3.    Melanoma

8.4.1.2.4.    Colorectal Cancer

8.4.1.2.5.    Gastric

8.4.1.2.6.    Others (Cervical, Kidney, Leukemia, etc.)

8.4.2.   The UK

8.4.2.1.    The UK Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Product Type

8.4.2.1.1.    Protein Biomarkers

8.4.2.1.2.    Genetic Biomarkers

8.4.2.1.3.    Other Cancer Biomarkers

8.4.2.2.    The UK Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Applications

8.4.2.2.1.    Breast Cancer

8.4.2.2.2.    Lung Cancer

8.4.2.2.3.    Melanoma

8.4.2.2.4.    Colorectal Cancer

8.4.2.2.5.    Gastric

8.4.2.2.6.    Others (Cervical, Kidney, Leukemia, etc.)

8.4.3.   Spain

8.4.3.1.    Spain Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Product Type

8.4.3.1.1.    Protein Biomarkers

8.4.3.1.2.    Genetic Biomarkers

8.4.3.1.3.    Other Cancer Biomarkers

8.4.3.2.    Spain Market Revenue (US$ Mn) and Forecasts, By Applications

8.4.3.2.1.    Breast Cancer

8.4.3.2.2.    Lung Cancer

8.4.3.2.3.    Melanoma

8.4.3.2.4.    Colorectal Cancer

8.4.3.2.5.    Gastric

8.4.3.2.6.    Others (Cervical, Kidney, Leukemia, etc.)

8.4.4.   Germany

8.4.4.1.    Germany Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Product Type

8.4.4.1.1.    Protein Biomarkers

8.4.4.1.2.    Genetic Biomarkers

8.4.4.1.3.    Other Cancer Biomarkers

8.4.4.2.    Germany Market Revenue (US$ Mn) and Forecasts, By Applications

8.4.4.2.1.    Breast Cancer

8.4.4.2.2.    Lung Cancer

8.4.4.2.3.    Melanoma

8.4.4.2.4.    Colorectal Cancer

8.4.4.2.5.    Gastric

8.4.4.2.6.    Others (Cervical, Kidney, Leukemia, etc.)

8.4.5.   Italy

8.4.5.1.    Italy Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Product Type

8.4.5.1.1.    Protein Biomarkers

8.4.5.1.2.    Genetic Biomarkers

8.4.5.1.3.    Other Cancer Biomarkers

8.4.5.2.    Italy Market Revenue (US$ Mn) and Forecasts, By Applications

8.4.5.2.1.    Breast Cancer

8.4.5.2.2.    Lung Cancer

8.4.5.2.3.    Melanoma

8.4.5.2.4.    Colorectal Cancer

8.4.5.2.5.    Gastric

8.4.5.2.6.    Others (Cervical, Kidney, Leukemia, etc.)

8.4.6.   Rest of Europe

8.4.6.1.    Rest of Europe Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Product Type

8.4.6.1.1.    Protein Biomarkers

8.4.6.1.2.    Genetic Biomarkers

8.4.6.1.3.    Other Cancer Biomarkers

8.4.6.2.    Rest of Europe Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Applications

8.4.6.2.1.    Breast Cancer

8.4.6.2.2.    Lung Cancer

8.4.6.2.3.    Melanoma

8.4.6.2.4.    Colorectal Cancer

8.4.6.2.5.    Gastric

8.4.6.2.6.    Others (Cervical, Kidney, Leukemia, etc.)

8.5.   Key Segment for Channeling Investments

8.5.1.   By Country

8.5.2.   By Product Type

8.5.3.   By Applications

9.    Asia Pacific Companion Diagnostic Cancer Biomarkers Market Analysis and Forecasts, 2018 – 2026

9.1.   Overview

9.1.1.   Asia Pacific Market Revenue (US$ Mn)

9.2.   Asia Pacific Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Product Type

9.2.1.   Protein Biomarkers

9.2.2.   Genetic Biomarkers

9.2.3.   Other Cancer Biomarkers

9.3.   Asia Pacific Market Revenue (US$ Mn) and Forecasts, By Applications

9.3.1.   Breast Cancer

9.3.2.   Lung Cancer

9.3.3.   Melanoma

9.3.4.   Colorectal Cancer

9.3.5.   Gastric

9.3.6.   Others (Cervical, Kidney, Leukemia, etc.)

9.4.   Asia Pacific Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Country

9.4.1.   China

9.4.1.1.    China Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Product Type

9.4.1.1.1.    Protein Biomarkers

9.4.1.1.2.    Genetic Biomarkers

9.4.1.1.3.    Other Cancer Biomarkers

9.4.1.2.    China Market Revenue (US$ Mn) and Forecasts, By Applications

9.4.1.2.1.    Breast Cancer

9.4.1.2.2.    Lung Cancer

9.4.1.2.3.    Melanoma

9.4.1.2.4.    Colorectal Cancer

9.4.1.2.5.    Gastric

9.4.1.2.6.    Others (Cervical, Kidney, Leukemia, etc.)

9.4.2.   Japan

9.4.2.1.    Japan Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Product Type

9.4.2.1.1.    Protein Biomarkers

9.4.2.1.2.    Genetic Biomarkers

9.4.2.1.3.    Other Cancer Biomarkers

9.4.2.2.    Japan Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Applications

9.4.2.2.1.    Breast Cancer

9.4.2.2.2.    Lung Cancer

9.4.2.2.3.    Melanoma

9.4.2.2.4.    Colorectal Cancer

9.4.2.2.5.    Gastric

9.4.2.2.6.    Others (Cervical, Kidney, Leukemia, etc.)

9.4.3.   India

9.4.3.1.    India Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Product Type

9.4.3.1.1.    Protein Biomarkers

9.4.3.1.2.    Genetic Biomarkers

9.4.3.1.3.    Other Cancer Biomarkers

9.4.3.2.    India Market Revenue (US$ Mn) and Forecasts, By Applications

9.4.3.2.1.    Breast Cancer

9.4.3.2.2.    Lung Cancer

9.4.3.2.3.    Melanoma

9.4.3.2.4.    Colorectal Cancer

9.4.3.2.5.    Gastric

9.4.3.2.6.    Others (Cervical, Kidney, Leukemia, etc.)

9.4.4.   Southeast Asia

9.4.4.1.    Southeast Asia Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Product Type

9.4.4.1.1.    Protein Biomarkers

9.4.4.1.2.    Genetic Biomarkers

9.4.4.1.3.    Other Cancer Biomarkers

9.4.4.2.    Southeast Asia Market Revenue (US$ Mn) and Forecasts, By Applications

9.4.4.2.1.    Breast Cancer

9.4.4.2.2.    Lung Cancer

9.4.4.2.3.    Melanoma

9.4.4.2.4.    Colorectal Cancer

9.4.4.2.5.    Gastric

9.4.4.2.6.    Others (Cervical, Kidney, Leukemia, etc.)

9.4.5.   Rest of Asia Pacific

9.4.5.1.    Rest of Asia Pacific Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Product Type

9.4.5.1.1.    Protein Biomarkers

9.4.5.1.2.    Genetic Biomarkers

9.4.5.1.3.    Other Cancer Biomarkers

9.4.5.2.    Rest of Asia Pacific Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Applications

9.4.5.2.1.    Breast Cancer

9.4.5.2.2.    Lung Cancer

9.4.5.2.3.    Melanoma

9.4.5.2.4.    Colorectal Cancer

9.4.5.2.5.    Gastric

9.4.5.2.6.    Others (Cervical, Kidney, Leukemia, etc.)

9.5.   Key Segment for Channeling Investments

9.5.1.   By Country

9.5.2.   By Product Type

9.5.3.   By Applications

10. Middle East and Africa Companion Diagnostic Cancer Biomarkers Market Analysis and Forecasts, 2018 – 2026

10.1. Overview

10.1.1. Middle East and Africa Market Revenue (US$ Mn)

10.2. Middle East and Africa Market Revenue (US$ Mn) and Forecasts, By Product Type

10.2.1. Protein Biomarkers

10.2.2. Genetic Biomarkers

10.2.3. Other Cancer Biomarkers

10.3. Middle East and Africa Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Applications

10.3.1. Breast Cancer

10.3.2. Lung Cancer

10.3.3. Melanoma

10.3.4. Colorectal Cancer

10.3.5. Gastric

10.3.6. Others (Cervical, Kidney, Leukemia, etc.)

10.4. Middle East and Africa Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Country

10.4.1. GCC Countries

10.4.1.1.  GCC Countries Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Product Type

10.4.1.1.1.  Protein Biomarkers

10.4.1.1.2.  Genetic Biomarkers

10.4.1.1.3.  Other Cancer Biomarkers

10.4.1.2.  GCC Countries Market Revenue (US$ Mn) and Forecasts, By Applications

10.4.1.2.1.  Breast Cancer

10.4.1.2.2.  Lung Cancer

10.4.1.2.3.  Melanoma

10.4.1.2.4.  Colorectal Cancer

10.4.1.2.5.  Gastric

10.4.1.2.6.  Others (Cervical, Kidney, Leukemia, etc.)

10.4.2. Southern Africa

10.4.2.1.  Southern Africa Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Product Type

10.4.2.1.1.  Protein Biomarkers

10.4.2.1.2.  Genetic Biomarkers

10.4.2.1.3.  Other Cancer Biomarkers

10.4.2.2.  Southern Africa Market Revenue (US$ Mn) and Forecasts, By Applications

10.4.2.2.1.  Breast Cancer

10.4.2.2.2.  Lung Cancer

10.4.2.2.3.  Melanoma

10.4.2.2.4.  Colorectal Cancer

10.4.2.2.5.  Gastric

10.4.2.2.6.  Others (Cervical, Kidney, Leukemia, etc.)

10.4.3. Rest of MEA

10.4.3.1.  Rest of MEA Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Product Type

10.4.3.1.1.  Protein Biomarkers

10.4.3.1.2.  Genetic Biomarkers

10.4.3.1.3.  Other Cancer Biomarkers

10.4.3.2.  Rest of MEA Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Applications

10.4.3.2.1.  Breast Cancer

10.4.3.2.2.  Lung Cancer

10.4.3.2.3.  Melanoma

10.4.3.2.4.  Colorectal Cancer

10.4.3.2.5.  Gastric

10.4.3.2.6.  Others (Cervical, Kidney, Leukemia, etc.)

10.5. Key Segment for Channeling Investments

10.5.1. By Country

10.5.2. By Product Type

10.5.3. By Applications

11. Latin America Companion Diagnostic Cancer Biomarkers Market Analysis and Forecasts, 2018 – 2026

11.1. Overview

11.1.1. Latin America Market Revenue (US$ Mn)

11.2. Latin America Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Product Type

11.2.1. Protein Biomarkers

11.2.2. Genetic Biomarkers

11.2.3. Other Cancer Biomarkers

11.3. Latin America Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Applications

11.3.1. Breast Cancer

11.3.2. Lung Cancer

11.3.3. Melanoma

11.3.4. Colorectal Cancer

11.3.5. Gastric

11.3.6. Others (Cervical, Kidney, Leukemia, etc.)

11.4. Latin America Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Country

11.4.1. Brazil

11.4.1.1.  Brazil Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Product Type

11.4.1.1.1.  Protein Biomarkers

11.4.1.1.2.  Genetic Biomarkers

11.4.1.1.3.  Other Cancer Biomarkers

11.4.1.2.  Brazil Market Revenue (US$ Mn) and Forecasts, By Applications

11.4.1.2.1.  Breast Cancer

11.4.1.2.2.  Lung Cancer

11.4.1.2.3.  Melanoma

11.4.1.2.4.  Colorectal Cancer

11.4.1.2.5.  Gastric

11.4.1.2.6.  Others (Cervical, Kidney, Leukemia, etc.)

11.4.2. Rest of Latin America

11.4.2.1.  Rest of Latin America Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Product Type

11.4.2.1.1.  Protein Biomarkers

11.4.2.1.2.  Genetic Biomarkers

11.4.2.1.3.  Other Cancer Biomarkers

11.4.2.2.  Rest of Latin America Companion Diagnostic Cancer Biomarkers Market Revenue (US$ Mn) and Forecasts, By Applications

11.4.2.2.1.  Breast Cancer

11.4.2.2.2.  Lung Cancer

11.4.2.2.3.  Melanoma

11.4.2.2.4.  Colorectal Cancer

11.4.2.2.5.  Gastric

11.4.2.2.6.  Others (Cervical, Kidney, Leukemia, etc.)

11.5. Key Segment for Channeling Investments

11.5.1. By Country

11.5.2. By Product Type

11.5.3. By Applications

12. Competitive Benchmarking

12.1. Player Positioning Analysis

12.2. Global Presence and Growth Strategies

13. Player Profiles

13.1. Abbott Laboratories, Inc.

13.1.1. Company Details

13.1.2. Company Overview

13.1.3. Product Offerings

13.1.4. Key Developments

13.1.5. Financial Analysis

13.1.6. SWOT Analysis

13.1.7. Business Strategies

13.2. Abnova Corporation

13.2.1. Company Details

13.2.2. Company Overview

13.2.3. Product Offerings

13.2.4. Key Developments

13.2.5. Financial Analysis

13.2.6. SWOT Analysis

13.2.7. Business Strategies

13.3. Agilent Technologies, Inc.

13.3.1. Company Details

13.3.2. Company Overview

13.3.3. Product Offerings

13.3.4. Key Developments

13.3.5. Financial Analysis

13.3.6. SWOT Analysis

13.3.7. Business Strategies

13.4. Almac Group

13.4.1. Company Details

13.4.2. Company Overview

13.4.3. Product Offerings

13.4.4. Key Developments

13.4.5. Financial Analysis

13.4.6. SWOT Analysis

13.4.7. Business Strategies

13.5. Arup Laboratories Inc.

13.5.1. Company Details

13.5.2. Company Overview

13.5.3. Product Offerings

13.5.4. Key Developments

13.5.5. Financial Analysis

13.5.6. SWOT Analysis

13.5.7. Business Strategies

13.6. Biomérieux SA

13.6.1. Company Details

13.6.2. Company Overview

13.6.3. Product Offerings

13.6.4. Key Developments

13.6.5. Financial Analysis

13.6.6. SWOT Analysis

13.6.7. Business Strategies

13.7. Danaher Corporation

13.7.1. Company Details

13.7.2. Company Overview

13.7.3. Product Offerings

13.7.4. Key Developments

13.7.5. Financial Analysis

13.7.6. SWOT Analysis

13.7.7. Business Strategies

13.8. Hoffmann-La Roche AG

13.8.1. Company Details

13.8.2. Company Overview

13.8.3. Product Offerings

13.8.4. Key Developments

13.8.5. Financial Analysis

13.8.6. SWOT Analysis

13.8.7. Business Strategies

13.9. Hologic Inc.

13.9.1. Company Details

13.9.2. Company Overview

13.9.3. Product Offerings

13.9.4. Key Developments

13.9.5. Financial Analysis

13.9.6. SWOT Analysis

13.9.7. Business Strategies

13.10. Illumina, Inc.

13.10.1. Company Details

13.10.2. Company Overview

13.10.3. Product Offerings

13.10.4. Key Developments

13.10.5. Financial Analysis

13.10.6. SWOT Analysis

13.10.7. Business Strategies

13.11. Myriad Genetics, Inc.

13.11.1.   Company Details

13.11.2.   Company Overview

13.11.3.   Product Offerings

13.11.4.   Key Developments

13.11.5.   Financial Analysis

13.11.6.   SWOT Analysis

13.11.7.   Business Strategies

13.12. Novartis AG

13.12.1.   Company Details

13.12.2.   Company Overview

13.12.3.   Product Offerings

13.12.4.   Key Developments

13.12.5.   Financial Analysis

13.12.6.   SWOT Analysis

13.12.7.   Business Strategies

13.13.   Qiagen N.V.

13.13.1.   Company Details

13.13.2.   Company Overview

13.13.3.   Product Offerings

13.13.4.   Key Developments

13.13.5.   Financial Analysis

13.13.6.   SWOT Analysis

13.13.7.   Business Strategies

13.14.   Sysmex Corporation

13.14.1.   Company Details

13.14.2.   Company Overview

13.14.3.   Product Offerings

13.14.4.   Key Developments

13.14.5.   Financial Analysis

13.14.6.   SWOT Analysis

13.14.7.   Business Strategies

13.15. Thermo Fisher Scientific Inc.

13.15.1.   Company Details

13.15.2.   Company Overview

13.15.3.   Product Offerings

13.15.4.   Key Developments

13.15.5.   Financial Analysis

13.15.6.   SWOT Analysis

13.15.7.   Business Strategies

 

 Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

At Absolute Markets Insights, we use both top-down and bottom-up approach for calculating the market estimates and market forecast data. We allocate year-on-year growth rate from 2018 to 2026 and reach to the calculations for the global CAGR. Basically for estimation of the products and applications, usually we follow bottom-up approach, where we track the trends in different regions and their countries. We track down the growth factors, restraints, rules & regulations and opportunities for each country  and its region and finally calculate the global numbers. We first track the growth for the U.S. and Rest of North America. With these factors we can estimate the growth and trend for North America, similar approach would be taken for Europe, Asia Pacific, Latin America and Middle East & Africa. Finally, through our home grown model we reach to estimation and forecasting of the global numbers.   

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews  are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends. 

Prominent participants in our primary research process include:

  • Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
  • Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

  • Reuters
  • Factiva
  • Bloomberg
  • One Source
  • Hoovers

 

Research Methodology

Methodology

Key Inclusions

Methodology

  • A PHP Error was encountered

    Severity: Notice

    Message: Undefined offset: 0

    Filename: pages/reportpage.php

    Line Number: 204

    Backtrace:

    File: /home/absolute/public_html/application/views/pages/reportpage.php
    Line: 204
    Function: _error_handler

    File: /home/absolute/public_html/application/controllers/Report.php
    Line: 153
    Function: view

    File: /home/absolute/public_html/index.php
    Line: 315
    Function: require_once